Dare Bioscience

Daré Bioscience is a mission-driven, clinical-stage biotech pioneering evidence-based therapeutics exclusively for women's health. The company has achieved a key milestone with the commercial launch of DARE to PLAY™ Sildenafil Cream, the first FDA-approved topical treatment for female sexual arousal disorder, while advancing a broad pipeline including hormone-free contraception and a novel HPV treatment. Its strategy centers on leveraging localized drug delivery platforms to improve safety and efficacy, targeting large, underserved markets with high unmet need. Operating as a lean, virtual R&D organization, Daré partners with CROs and leverages non-dilutive funding to advance its programs toward commercialization.

Proprietary intravaginal ring (IVR) for sustained drug delivery and bioadhesive hydrogel technology for localized, on-demand topical administration, both focused on the female reproductive tract.

Competition varies by program, ranging from large pharma in contraception (Bayer, Merck) to unregulated wellness products in sexual health. Daré's key differentiators are its FDA-approved, evidence-based approach, proprietary delivery platforms, and focused expertise in the OB/GYN channel, setting it apart from marketing-driven 'femtech' companies.